跳至主要内容
临床试验/NL-OMON33661
NL-OMON33661尚未招募不适用

Phase I/II study of combined treatment with AT-101, cisplatin and radiotherapy in patients with locally advanced head and neck cancer - AT-101, cisplatin and radiotherapy in head and neck cancer

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Histologically proven squamous cell carcinoma of the head and neck
  • Oral cavity, oropharyngeal, or hypopharyngeal carcinoma
  • Inoperable TNM stage III/IV, M0
  • Patient must have measurable disease
  • Age > 18 years
  • Performance status WHO 0-2
  • No prior r adiation therapy to head and neck region
  • No prior cisplatin-based chemotherapy
  • Adequate laboratory results:
  • - WBC > 4.0 x 10E9/l
  • - platelets > 100 x 10E9/l
  • - calculated or 24 hour creatinine clearance > 50 ml/min
  • - ASAT/ALAT < 2.5 times upper limit of normal range
  • - Bilirubin < 1.5 x upper limit of institution's normal range
  • Willingness to use contraception by a method that is deemed effective by the Investigator throughout the treatment period and for at least 30 days following the last dose of therapy
  • Willing and able to undergo blood sampling for pharmacokinetics
  • Signed written informed consent before entry into study.
  • Entry criteria for translational research:
  • - Willing and able to undergo blood sampling, harvesting of buccal smears and tumor biopsy (mandatory)
  • - Willing and able to undergo skin biopsy and nuclear scanning (optional)

排除标准

  • Breast feeding or pregnancy
  • Uncontrolled arrhythmia
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, or partial or complete small bowel obstruction
  • Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification.
  • Known active symptomatic fungal, bacterial and/or viral infection including active HIV
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验

Phase I/II study of combined treatment with AT-101,... | 临床试验